<DOC>
	<DOCNO>NCT01885806</DOCNO>
	<brief_summary>We aim evaluate safety efficacy repetitive transcranial magnetic stimulation ( rTMS ) apathy treatment patient Alzheimer 's disease ( AD ) . We hypothesize rTMS superior placebo reduce apathy symptom severity patient AD .</brief_summary>
	<brief_title>Repetitive Transcranial Magnetic Stimulation Apathy Treatment Alzheimer 's Disease</brief_title>
	<detailed_description>This study aim enroll 40 patient mild moderate Alzheimer 's disease apathy symptom randomize receive rTMS sham procedure . Subjects randomize two arm ( rTMS sham procedure ) 1:1 proportion . Eligibility criterion : - Diagnosis Alzheimer 's disease , mild moderate stage ( MMSE range 10 20 ) ; - Diagnosis apathy ; - age 60 85 years-old ; - On stable dos cholinesterase inhibitor ( donepezil , rivastigmine , galantamine ) memantine least 6 month prior enrollment ; The primary outcome measure Apathy Inventoire . Secondary outcome measure NPI score , ADAS-cog score Zarit Burden Scale score .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Age 60 85 yearsold Mild moderate Alzheimer 's disease ( MMSE score 10 20 ) Apathy diagnosis On stable dos cholinesterase inhibitor ( donepezil , galantamine , rivastigmine ) and/or memantine least 6 month prior enrollment history epilepsy convulsion History migraine headache episode twice per week History neurodegenerative disease Alzheimer 's disease Current use first generation antipsychotic , clozapine , tricyclic drug anticonvulsant History cerebral ischemic episode</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Apathy ; Alzheimer 's disease ; Cognition ; Burden Care</keyword>
</DOC>